Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Parvimonas micra as a putative non-invasive faecal biomarker for colorectal cancer
Umeå University, Faculty of Medicine, Department of Medical Biosciences, Pathology.
Umeå University, Faculty of Medicine, Department of Medical Biosciences, Pathology.
Umeå University, Faculty of Medicine, Department of Medical Biosciences, Pathology.
Umeå University, Faculty of Medicine, Department of Medical Biosciences, Pathology.
Show others and affiliations
2020 (English)In: Scientific Reports, E-ISSN 2045-2322, Vol. 10, no 1, article id 15250Article in journal (Refereed) Published
Abstract [en]

The use of faecal microbial markers as non-invasive biomarkers for colorectal cancer (CRC) has been suggested, but not fully elucidated. Here, we have evaluated the importance of Parvimonas micra as a potential non-invasive faecal biomarker in CRC and its relation to other microbial biomarkers. The levels of P. micra, F. nucleatum and clbA+bacteria were quantified using qPCR in faecal samples from a population-based cohort of patients undergoing colonoscopy due to symptoms from the large bowel. The study included 38 CRC patients, 128 patients with dysplasia and 63 controls. The results were validated in a second consecutive CRC cohort including faecal samples from 238 CRC patients and 94 controls. We found significantly higher levels of P. micra in faecal samples from CRC patients compared to controls. A test for P. micra could detect CRC with a specificity of 87.3% and a sensitivity of 60.5%. In addition, we found that combining P. micra with other microbial markers, could further enhance test sensitivity. Our findings support the potential use of P. micra as a non-invasive biomarker for CRC. Together with other microbial faecal markers, P. micra may identify patients with "high risk" microbial patterns, indicating increased risk and incidence of cancer.

Place, publisher, year, edition, pages
Nature Publishing Group, 2020. Vol. 10, no 1, article id 15250
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-176065DOI: 10.1038/s41598-020-72132-1ISI: 000573742900024PubMedID: 32943695Scopus ID: 2-s2.0-85091192879OAI: oai:DiVA.org:umu-176065DiVA, id: diva2:1498815
Available from: 2020-11-05 Created: 2020-11-05 Last updated: 2024-03-26Bibliographically approved
In thesis
1. Gut microbiota in colorectal cancer: The importance of Parvimonas micra
Open this publication in new window or tab >>Gut microbiota in colorectal cancer: The importance of Parvimonas micra
2024 (English)Doctoral thesis, comprehensive summary (Other academic)
Alternative title[sv]
Tarmfloran hos patienter med kolorektalcancer : betydelsen av Parvimonas micra
Abstract [en]

Colorectal cancer (CRC) is a heterogenous disease consisting of multiple molecular subtypes, each of which has diverse treatment responses and prognoses. The importance of the gut microbiota in CRC development and progression has undergone increasing recognition in recent years, with a structural segregation in terms of microbial composition between CRC patients and healthy controls. However, many questions remain before a full understanding of the impact of the gut microbiota on CRC is reached. The overall aim of this thesis was to explore the role of gut microbes in CRC, including their potential as CRC biomarkers and associations with clinicopathological, immunological, and molecular traits of CRC. A particular focus was the CRC-associated oral pathogen Parvimonas micra.

To investigate faecal microbiota as a potential biomarker for CRC, we studied the presence of specific bacteria in faeces from CRC patients and controls using qPCR. We found higher levels of P. micra in faecal samples from CRC patients than from control patients. A test for high levels of P. micra was able to identify CRC with a specificity of 87.3% and a sensitivity of 60.5%. Adding the oral pathogen Fusobacterium nucleatum, colibactin-producing bacteria, and faecal haemoglobin to the test enhanced its sensitivity.

We further aimed to explore the associations of P. micra and F. nucleatum with molecular subtypes of CRC and the tumour immune response. The levels of P. micra and F. nucleatum, as analysed by qPCR in both faeces and tumour tissue from CRC patients, were found to be positively correlated. High levels of intratumoural P. micra and F. nucleatum were associated with tumours of the microsatellite instable subtype and BRAF-mutated tumours. For F. nucleatum, an additional association with right-sided tumours was found. Moreover, both P. micra and F. nucleatum in tumour tissue were associated with the immune-activated consensus molecular subtype (CMS) 1 subtype of CRC. In line with this finding, we found novel associations between intratumoural P. micra and specific immune traits, which were evaluated by flow cytometry, indicating an active immune response in CRC. These results were further confirmed using transcriptomics. However, no associations with specific immune traits were found for F. nucleatum.

We also investigated associations between faecal and intratumoural levels of P. micra and F. nucleatum and survival in CRC patients. CRC patients with high levels of intratumoural P. micra and F. nucleatum showed reduced five-year cancer-specific survival. This association remained significant for P. micra in multivariable analysis. No associations with cancer-specific survival were found for levels of P. micra and F. nucleatum in faeces.

To investigate the faecal microbial landscape of CRC patients on a larger scale, we used 16S rRNA sequencing. Network analysis revealed a cluster of associated bacteria, including P. micra and F. nucleatum, as well as other CRC-related pathogens such as Bacteroides fragilis, Peptostreptococcus stomatitis, and Porphyromonas spp. Furthermore, beta-diversity analysis indicated a significantly different gut microbial composition depending on tumour location and microsatellite instability status. Interestingly, three of the six annotated species most strongly associated with microsatellite instable tumours were also present in the cluster: P. micra, F. nucleatum, and P. stomatis.

In conclusion, our results suggest P. micra as a putative candidate for a future non-invasive microbial test panel for detection of CRC. Moreover, our results indicate that intratumoural P. micra and F. nucleatum are associated with immune-active subtypes of CRC, including microsatellite instable tumours and tumours of the CMS1 subtype, as well as decreased patient survival. Furthermore, P. micra and F. nucleatum were found to be associated with a cluster of other CRC-related oral pathogens. An improved understanding of the role of the gut microbiota in tumour progression may lead to the identification of important biomarkers for CRC disease and outcome, as well as potential targets for future therapy.

Place, publisher, year, edition, pages
Umeå: Umeå University, 2024. p. 53
Series
Umeå University medical dissertations, ISSN 0346-6612 ; 2286
Keywords
Colorectal cancer, mucosal microbiota, Parvimonas micra, Fusobacterium nucleatum, immunity, survival
National Category
Biomedical Laboratory Science/Technology
Research subject
biomedical laboratory science
Identifiers
urn:nbn:se:umu:diva-222737 (URN)978-91-8070-300-0 (ISBN)978-91-8070-299-7 (ISBN)
Public defence
2024-04-26, Hörsal Betula, byggnad 6M, Umeå, 13:00 (English)
Opponent
Supervisors
Available from: 2024-04-05 Created: 2024-03-26 Last updated: 2024-03-28Bibliographically approved

Open Access in DiVA

fulltext(1261 kB)285 downloads
File information
File name FULLTEXT01.pdfFile size 1261 kBChecksum SHA-512
8efef44d61263bc033021f88e99c2364828bb4b8650367def57a227f8a258653c81b07e8250d23c24c781b38e76c1d18cf153a20ec3b5513657f4f79c15a86a9
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Löwenmark, ThyraLöfgren Burström, AnnaZingmark, CarlEklöf, VincyWai, Sun NyuntLarsson, PärLjuslinder, IngridEdin, SofiaPalmqvist, Richard

Search in DiVA

By author/editor
Löwenmark, ThyraLöfgren Burström, AnnaZingmark, CarlEklöf, VincyWai, Sun NyuntLarsson, PärLjuslinder, IngridEdin, SofiaPalmqvist, Richard
By organisation
PathologyDepartment of Molecular Biology (Faculty of Medicine)Oncology
In the same journal
Scientific Reports
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 285 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 474 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf